Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A...

{
  "signal_id": "5d7ef205-8dba-2721-90c5-f27eae9d9bdf",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-07-30T14:31:00+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/inflammatory-bowel-disease-market-to-experience-strong-uptake-during-the-forecast-period-20262036-driven-by-development-of-next-generation-therapies-targeting-il-23-tl1a-and-s1p-pathways--delveinsight-302838594.html",
    "title": "Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight",
    "excerpt": "The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging therapies such as ABX464 (Abivax), Tulisokibart (Merck), RHB-204 (RedHill Biopharma), TEV-574 (Teva Pharmaceuticals/Sanofi), and others, increasing adoption of personalized treatment strategies, and supportive regulatory approvals are further accelerating market expansion. LAS VEGAS , July 30, 2026 /PRNewswire/ -- Recently published Inflammatory Bowel Disease Market Insights report includes a comprehensive understanding of current treatment practices, inflammatory bowel disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Inflammatory Bowel Disease Market Summary Discover what is the effectiveness of Johnson & Johnson's medications for managing symptoms of inflammatory bowel disease @ https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market Key Factors Driving the Growth of the Inflammatory Bowel Disease Market According to Aparna Thakur, Project Manager of Forecasting at DelveInsight, the entry of late-stage and next-generation...",
    "product": "Tulisokibart",
    "summary": "Merck is developing Tulisokibart (MK-7240), an investigational humanized monoclonal antibody for immune-mediated inflammatory disorders, with ongoing Phase III studies for Crohn's disease and ulcerative colitis.",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS1196378/logo-png.jpg?id=OA2811715&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Tulisokibart",
      "full_text": "Tulisokibart (MK-7240)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-07-30T14:31:00Z",
    "article_sentence": "Merck's Tulisokibart (MK-7240) is an investigational humanized monoclonal antibody being developed to treat immune-mediated inflammatory disorders, with a primary focus on inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis."
  }
}

curl https://signals.autobound.ai/v1/signals/5d7ef205-8dba-2721-90c5-f27eae9d9bdf \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","limit":20}'